Buscopan Dosing for Abdominal Pain
For acute abdominal pain in adults, Buscopan (hyoscine butylbromide) should be dosed at 20 mg intravenously for rapid relief, or 10 mg orally three times daily for recurrent cramping pain, with onset of action within 10-30 minutes.
Intravenous Dosing
The standard IV dose is 20 mg administered as a single slow intravenous injection 1. This provides rapid pain relief with onset of action noticeable within 10 minutes and achieving 42-78% pain reduction within 30 minutes for conditions like biliary colic 2. For renal colic, approximately 90% of patients show good to moderate analgesic response after 30 minutes 2.
- Onset: Pain relief begins within 10-15 minutes
- Peak effect: 30 minutes post-injection
- Duration: Effects last approximately 4 hours
The FDA label for veterinary use indicates 0.3 mg/kg body weight IV 1, but human dosing is standardized at 20 mg regardless of weight for most indications.
Oral Dosing
For recurrent cramping abdominal pain, the recommended dose is 10 mg three times daily (t.d.s.) 3. This regimen demonstrated statistically significant reduction in pain intensity (Visual Analogue Scale decrease of 2.3 cm vs 1.9 cm for placebo, p<0.0001) and pain frequency when used continuously for 3 weeks 3.
On-Demand Dosing
For self-reported functional cramping pain, patients can use 20-100 mg/day on demand 4:
- Initial dose: 20 mg at onset of pain
- Additional doses: Up to 4 additional 20 mg doses every 30 minutes if needed
- Maximum daily dose: 100 mg
- Clinically relevant pain reduction (≥2 points on 11-point scale) occurs at 45 minutes vs 60 minutes for placebo 4
Clinical Context and Evidence Quality
Important caveats:
Limited efficacy in some conditions: A 2024 double-blind RCT found that 20 mg IV HBB showed no statistically or clinically significant difference compared to placebo for acute gastroenteritis pain in the emergency department 5. This suggests HBB may be more effective for spasmodic pain (biliary/renal colic) than inflammatory conditions.
IBS guidelines support use: The 2022 AGA guidelines for IBS recommend antispasmodics (including hyoscine) with conditional recommendation based on low-certainty evidence 6. The Cochrane Review showed improvement in abdominal pain (RR 0.74; 95% CI 0.59-0.93) but with very low certainty due to risk of bias 6.
Combination therapy: HBB 10 mg + paracetamol 500 mg (Buscopan Plus) is available and shows similar efficacy to either agent alone for recurrent cramping pain 3, 7. For dysmenorrhea, this combination achieved 65.8% pain reduction at 4 hours 7.
Safety Profile
HBB is well-tolerated with mild, self-limiting anticholinergic effects 2:
- Common: Dry mouth, blurred vision, pupillary dilation (transient)
- Rare: Dizziness, tachycardia
- No serious adverse events reported in clinical trials 6, 3
- Does not cross blood-brain barrier, avoiding CNS effects 2
Contraindications: Avoid in patients with narrow-angle glaucoma, myasthenia gravis, megacolon, or mechanical GI obstruction.
Practical Algorithm
For acute severe pain (biliary/renal colic):
- Give 20 mg IV slowly
- Expect relief within 10-30 minutes
- May repeat once if inadequate response after 30 minutes
For recurrent functional cramping:
- Start 10 mg PO three times daily with meals
- Continue for 1-3 weeks
- Alternatively, use on-demand: 20 mg at pain onset, repeat every 30 min up to 100 mg/day
For IBS-related pain:
- Use as part of antispasmodic strategy per AGA guidelines 6
- 10 mg three times daily is standard
- Consider combination with dietary modifications and other IBS therapies
The evidence strongly supports HBB for spasmodic abdominal pain, particularly biliary and renal colic, with rapid onset and good tolerability 2, 8. However, clinicians should recognize its limitations in inflammatory conditions like gastroenteritis 5.